Until recently, concepts of care for people with heart failure had rarely included preparation for unavoidable imminent death or caring for the dying. The purpose of this review is to provide an update on current end-of-life issues specific to heart failure patients.
INTRODUCTION
Heart failure is principally an incurable and progressive disease. Thus, once diagnosed, it will be present in a person's life until death caused by heart failure itself, a concomitant disease or another reason, such as an accident. Sudden cardiac death (SCD) can confound any scenario at any point. Increasing numbers of people with heart failure have had different cardiac devices implanted, improving quality of life and/or survival. Eventually, at end of life (EoL), when death becomes imminent, these devices preventing death may prolong dying, rather than life. For this reason, the modification of the activity of these devices should be considered and discussed with the patient in advance.
The purpose of this article is to review current EoL issues in heart failure patients. Symptom control, however crucially important, will not be discussed because of the limited scope of this article.
MORTALITY
Despite progress in management, the mortality for heart failure, although improving, remains high.
Three-year mortality is about 25% [1 & ]. The highest mortality is observed shortly after the first acute heart failure hospitalization (10-20% die within 1 month) [2] . The latter prognosis seems to be better if only the patients who survive this vulnerable period are taken into account, after those with 'malignant disease' have already died [3] . The average life expectancy after the first episode of heart failure is 2.34 years in men and 1.79 years in women, and 1.1 year after considering patients as eligible for heart transplantation and 9.4 months for those who are too ill to be put on the waiting list [4, 5] . population in recent decades, the contribution of SCD to general mortality has been decreasing; noncardiovascular mortality has been rising, and progressive heart failure remains stable [7] . Rates of SCD have improved due to both medical treatment (beta-blockers) decreasing the risk of malignant arrhythmia and devices [implantable cardioverter defibrillators (ICDs)] or cardiac resynchronisation therapy (CRT) with defibrillating function (CRT-D)] terminating arrhythmia. It was supposed that the implantation of ICDs would shift the reasons for mortality towards progressive heart failure, but this has not been observed [6] . People saved from SCD tend to die for non heart failure related reasons. One possible explanation for this shift is the aging of both the general and heart failure populations. Multimorbidity and incidence of heart failure rise with age, so the average heart failure patient suffers from more than four comorbidities. The heart failure population can be divided into two groups: those with impaired systolic function of the left ventricle [systolic heart failure, or heart failure with reduced ejection fraction (HFREF)] and those with impaired filling of the left ventricle [diastolic heart failure or heart failure with preserved ejection fraction (HFPEF)] [8, 9] . The distribution of causes of
KEY POINTS
Patients with advanced heart failure die from cardiovascular and a growing proportion of noncardiovascular causes.
There is a need for better anticipatory communication about possible disease trajectories.
Modern management (in the first instance implantable devices) saves life but eventually influences scenarios for dying. Prompt advance care planning is recommended.
Technology allows postponing death, sometimes at the cost of a good quality of life. The possibility of influencing the length of a very limited life involves ethical dilemmas. death is related to the type of heart failure ( Table 1 ). The general mortality is similar in both groups (Fig. 1 ). People with HFREF die more frequently from cardiovascular causes (heart failure and SCD), and those with HFPEF from noncardiovascular ones and SCD. If only cardiovascular deaths are considered, the proportion of SCD becomes comparable for both groups, although heart failure deaths are still more common in systolic heart failure. The main form of cardiovascular death is progressive heart failure in HFREF and SCD in HFPEF. The rate of noncardiovascular deaths in HFPEF rises proportionally with age. The most common concomitant diseases leading to death in HFPEF are cancer and infection [8, 10, 11] .
MODES OF HEART FAILURE DEATH
Dying from progressive heart failure can be characterised by low cardiac output (CO) with or without secondary end-organ dysfunction, congestion, or a combination of both. The event directly terminating life can be bradyarrhythmia, tachyarrhythmia (ventricular fibrillation), or pulseless rhythm (electromechanical dissociation). The most common form of heart failure death in HFREF is low CO, alternatively with congestion, whereas in HFPEF it is congestion alternatively with low CO [12] . In both forms of heart failure, CO and stroke volume can be reduced to a similar degree ( Table 2 ). In systolic heart failure, the volume of blood pumped out with one contraction (stroke volume, SV) corresponding with 10-15% of left ventricle end diastolic volume (being described as ejection fraction, EF) can be equal with 50% of small left ventricle end diastolic volume typically seen in HFPEF. If low CO leads to secondary dysfunction of other organs, patients will present additional symptoms of renal or liver failure, impaired digestion, or somnolence. If local factors (such as atherosclerotic plaques) further compromise flow, further deterioration of organ function up to necrosis is seen (intestinal infarction, limb necrosis, or stroke). Sometimes, additional thromboembolic incidents may complicate the above scenarios. Decreased CO activates the neurohormonal axis and leads to salt and water conservation, vasoconstriction, and elevation of ventricular filling pressure, with subsequent congestion in pulmonary or systemic circulation [8] .
DYING TRAJECTORIES
Death from heart failure is usually seen as unpredictable, with about 50% of deaths being sudden. The Seattle Heart Failure Model does not seem to be the optimal assessment tool for the stratification of risk of death respective planning EoL care. Using the Seattle Heart Failure Model, only 0.4% of heart failure patients would be classified as very high risk (1-year mortality of 84%) and 3.3% as intermediate risk (mortality >50%) [13] . A recent retrospective analysis investigating the pattern of how heart failure patients approached death showed that only 21% of deaths were sudden. The authors identified five EoL trajectories ( 
NEED FOR BETTER COMMUNICATION
Medical staff are convinced that their communication with patients is excellent. In the patients' opinion, however, communication is satisfactory only in respect to everyday care, but not EoL issues. Using the Quality of Communication questionnaire, patients assessed (0 ¼ worst; 10 ¼ best) the communication with the treating physician on care as having a median score of 8.0 (7.0-8.7) but on EoL with a median score of 0.0 (0.0-1.3) [15] . Advance directives, referring to preferences regarding possible needs for therapeutic interventions such as cardiopulmonary resuscitation or mechanical ventilation, should be discussed with patients and their families and the validity of the orders checked regularly. In addition to general issues, diseasespecific matters, such as those related to implantable devices (both electronic and mechanical), should be addressed as well. Evidence shows that most patients with implanted ICD are not aware of the possibility of modification of its activity. This is not consistent with recent efforts to move conversations about ICD deactivation to a time prior to implantation. Interestingly, advance directives still play a limited role, being prepared only by 41% of heart failure patients in the USA and 3.9% in The Netherlands [15, 16] . The presence of advance directives decreases the intensity of treatment (reduction in ICU hospitalizations and mechanical ventilation), but not the frequency of hospital admissions.
For good decision making, patients need precise information about the disease, prognosis, possible interventions, and the probabilities of their positive and negative outcomes. Patients receive scant information concerning the probability of success of potential resuscitation or ICD intervention. They perceive resuscitation as noninvasive intervention, having a high probability of success. Patients imagine that ICDs save 50 lives per 100 patients over 5 years. In fact, absolute risk of death reduction is only 5-7% during 3-5 years (this corresponds to 23-36% relative risk reduction) [17, 18] . The prognosis is only rarely discussed with patients because many physicians think it is too unpredictable and will diminish hope [19] . Of course, not every patient expects such discussion and this has to be respected. However, the principle of 'being prepared for the worst whilst hoping for the best' leaves a big space in which to recognise the need for conversation [20] .
As the disease progresses, the goals of treatment should be reevaluated, as previous aims can become unrealistic and reflect false hope. Attempts to achieve them can lead to medical futility. As a consequence, the imminently dying are treated at full intensity with the attitude of implementing anything possible. The content of communication should be adapted to the stage of advancement of the disease. In the less-advanced stages, it is more important to discuss the risk of sudden death, whereas in later disease progression, slow decline and low CO trajectory become more necessary to discuss. The treatment preferences of patients can never be assumed automatically. It is generally believed that elderly persons will prioritise quality over length of life. Studies show, however, that the vast majority (74%) of elderly people with heart failure is not willing to trade-off survival time for quality of life [21] .
APPROACHING DEATH WITH ACTIVE IMPLANTABLE DEVICES
Implantable cardiological devices can be electronic [cardiovascular implantable electronic devices (CEID)] or mechanical [ventricular assist devices (VADs)]. They improve or support functioning of the heart (CRT or VADs) or decrease the risk of SCD (ICDs). ICDs can terminate potentially fatal arrhythmia using two different patterns of intervention, depending on the type of arrhythmia and programming: high-energy electrical shock (usually painful) or low-energy antitachycardia pacing (not noticeable). As patients approach death from a cause that is not amenable to a device, some of their functions (VADs and shocks from ICDs, or CRT-D), if left unadjusted, can worsen the dying scenario. The shock does not treat the underlying condition, but simply terminates arrhythmia. If arrhythmia is an element of terminal agony, the device is attempting to 'resuscitate' the dying person and returns him or her to a state of agony. In such conditions, an ICD no longer provides holistically considered benefits. The deactivation of high energy therapies allows a natural death that is unavoidable and imminent. However, discussion on this topic is not easy, either for the patient and/or his or her representative or for the physician. Patients make the decision more intuitively than rationally, even if they seem to understand the role of an ICD. Asked about deactivating their ICD, they usually answer 'no' because the ICD prevents SCD, which is intuitively understood as preventing any death. The same person asked about preferring a slow death, however, usually answers 'no' as well. These answers are contradictory and reflect misunderstanding of the essence of the two questions [22] . This shows how important is pattern of the communication.
In decision-making regarding modification of cardiovascular implantable electronic device activity, every kind of intervention, having various consequences, needs separate consideration even if delivered by one device. Pacing (which can be delivered by pacemakers, CRT, and ICDs) per se does not have to interfere with the dying process because the sensitivity of the heart is falling, and the probability of effective stimulation decreases along with the changes in homeostasis typically seen during dying (such as acidosis or dyselectrolytaemia). The rising stimulation threshold makes the heart less susceptible to pacing, thus evoking prolonged dying is less likely. CRT is a special type of stimulation, restoring the synchrony of left ventricle contraction and improving the efficacy of the work of the heart. Both forms of pacing -antibradycardia and resynchronization -prevent symptoms, and do not cause any suffering during dying. Loss of function can itself be a cause of suffering: syncope in the case of the discontinuation of antibradycardia pacing and a escalation of heart failure symptoms caused by loss of resynchronization [23 && ]. The modification of high-voltage (shock) and low-voltage (antitachycardia pacing) interventions of ICD and CRT-D needs separate consideration. It is imaginable that one would like to avoid painful interventions and keep antitachycardia pacing active. This allows the patient to possess a device that is not useless, whilst being protected from device-induced suffering. Of patients with a fully active device, 'only' 21% will receive shocks whilst dying [17] . Other terminal events -bradycardia or pulseless rhythm -do not trigger ICD intervention. It had been anticipated that heart failure patients approaching EoL would wish to modify ICD function quite often. Available data are quite divergent and show that 30-71% of questioned heart failure patients can imagine requesting to switch off an ICD in at least one clinical scenario of imminent death or suffering [18, 24, 25] . It is hypothesised that the exceptionally high proportion of patients potentially expecting ICD deactivation (71%) presented in one study was the result of scheduled education being an obligatory part of the decision-making process [24] . The National Quality Forum in the United States has proposed using deactivation (high energy interventions) of ICDs as a quality indicator of palliative care for hospitalized persons with an anticipated death (http://www.qualityforum.org/ Projects/Palliative_Care_and_End-of-Life_Care.aspx accessed August 2014). The proposed quality factor is the proportion of dying patients who have an ICD deactivated or in whom the reasons for not doing so have been documented. A project was developed to improve quality regarding ICDs in hospice inpatients and in home care on the basis of three elements: education, documentation, and clinical tools. If deactivation was not obtained in the preferred electronic way, the usage of magnets was available. Placing a magnet on the device could be performed on a patient's verbal instruction. To make this possible, every clinician treating patients was equipped with ICD-deactivation magnets, and these were also left in patients' homes to prevent repeated shocks in the case of an emergency. These three interventions (education, documentation, and clinical tools) and the presence of the policy allowed an almost four-fold increase in the frequency of dying with a deactivated ICD [26 & ].
Another type of device that changes the trajectory for heart failure patients is a VAD, primarily used as a bridge to transplantation but being used more often as a long-term destination therapy. The issue was discussed in detail recently by one of the coauthors (Jaarsma T) [27 & ]. Decisions on discontinuing VADs are complex and sometimes controversial, as the device replaces native physiological heart function in heart failure and its deactivation is a lifeending intervention. Rady and Verheijde [28 && ] postulate that the onset of a new lethal pathophysiology (i.e., circulatory shock, massive haemorrhage, overwhelming infection, multiple organ failure, or terminal cancer) is a key criterion in assessing the permissibility of the life-ending discontinuation of a VAD and in differentiating natural death from assisted death. Medicare and Medicaid in the United States have stipulated that centres implanting VADs as a destination therapy include a palliative care specialist as a member of the team, due to the fact that durable mechanical circulatory support might significantly alter EoL trajectory (www.cms.gov/ medicare-coverage-database/details/nca-proposeddecision-memo.aspx?NCAId=268).
CONCLUSION
The awareness that heart failure can progress with specific but diverse trajectories is increasing. Dying is, of course, an integral part of each trajectory. As modern drug and device therapies influence the whole disease trajectory, they can significantly influence the quality of dying. A decreasing proportion of heart failure patients is dying from SCD, raising the number of people living with heart failure who will approach death due to other, noncardiological reasons. A large proportion of the latter will have active implantable cardiac devices in place during the phase of dying. Support for people dying from or with heart failure can and should require the reevaluation of treatment goals, symptom management. Additionally, patients having the implantable devices modification of their activities should be discussed (preferentially in advance) and if expected performed at appropriate time. To enable good EoL care, the participation of patients in a decision-making process on the basis of good communication is crucial. In an attempt to identify unmet needs of patients and their relatives and to develop more effective modes of caring for them, the new Task Force on Palliative Care for People with Heart Disease was created in 2014 under the mutual auspices of the European Association for Palliative Care and Heart Failure Association.
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